Digital epidemiology is the process of investigating the dynamics of disease-related patterns, both social and clinical, as well as the causes of these trends in epidemiology. Digital epidemiology, utilising big data from a variety of digital sources, has emerged as a viable method for early detection and monitoring of viral outbreaks. The present review gives an overview of digital epidemiology, emphasising its importance in the timely detection of infectious disease outbreaks. Researchers may discover and track outbreaks in real time using digital data sources such as search engine queries, social media trends, and digital health records. However, data quality, concerns about privacy, and data interoperability must be addressed to maximise the effectiveness of digital epidemiology. As the global landscape of infectious diseases evolves, integrating digital epidemiology becomes critical to improving pandemic preparedness and response efforts. Integrating digital epidemiology into routine monitoring systems has the potential to improve global health outcomes and save lives in the event of viral outbreaks.

Astrovirus MLB2 (AstV-MLB2) is an emerging gastrointestinal virus causing meningitis and disseminated infections. Currently, there are no vaccine-based therapies available for AstV-MLB2. This study aims to develop multi-epitope vaccine models using candidate proteins from AstV-MLB2. Highly immunogenic epitopes (IC₅₀ < 200 μM) exhibiting conservation, antigenicity, and non-allergenicity were called from these proteins. Additionally, the selection criteria for epitopes were based on their potential to trigger immune cells and stimulate IFN-γ-mediated immune responses. The model vaccine constructs were designed from identified lead epitopes, along with immune-enhancer adjuvants and linker sequences. The proposed vaccine models were assessed for allergenicity, antigenicity, and structural integrity to ensure their safety and effectiveness. The binding potential of the vaccine models to HLA and TLR-4 immune cell receptors was evaluated to identify their capacity to stimulate immune responses. Among several raw constructs, MLB2-V1 and MLB2-V2 were identified as potential vaccine candidates due to their non-allergenic features, enhanced antigenic properties, and structural stability. Both these constructs were extensively evaluated and predicted to effectively bind to and interact with immune cell receptors, potentially triggering cellular and innate immune responses. Additionally, the prioritized constructs were deemed suitable for cloning and expression using recombinant DNA systems. The model vaccine constructs showed promise, warranting further investigation into their immune efficacy against MLB2-mediated infections through experimental assays and clinical trials.

Alport syndrome (AS) is a rare genetic disorder categorized by the progressive loss of kidney function, sensorineural hearing loss and eye abnormalities. It occurs due to mutations in three genes that encode for the alpha chains of type IV collagen. Globally, the disease is classified based on the pattern of inheritance into X-linked AS (XLAS), which is caused by pathogenic variants in COL4A5, representing 80% of AS. Autosomal recessive AS (ARAS), caused by mutations in either COL4A3 or COL4A4, represents 15% of AS. Autosomal dominant AS (ADAS) is rare and has been recorded in 5% of all cases due to mutations in COL4A3 or COL4A4. This review provides updated knowledge about AS including its clinical and genetic characteristics in addition to available therapies that only slow the progression of the disease. It also focuses on reported cases in Saudi Arabia and their prevalence. Moreover, we shed light on advances in genetic technologies like gene editing using CRISPR/Cas9 technology, the need for an early diagnosis of AS and managing the progression of the disease. Eventually, we provide a few recommendations for disease management, particularly in regions like Saudi Arabia where consanguineous marriages increase the risk.

Introduction: The presence of cytomegalovirus (CMV) immunoglobulin M (IgM) in human immunodeficiency virus (HIV)-positive individuals indicates an active infection or reactivation of the virus. Methodology: This study investigated the seroprevalence of CMV IgM antibodies among HIV-positive individuals attending the Ahmadu Bello University Teaching Hospital in Nigeria. Results: Fifty nine out of 92 participants who were tested with an enzyme-linked immunosorbent assay (ELISA) were positive for CMV IgM, resulting in a prevalence rate of 64.1%. Analysis of sociodemographic variables revealed a statistically significant association between CMV IgM seropositivity, and both gender and residence of the participants. Clinical variables also indicated a significant association between CMV IgM seropositivity and the duration of HIV infection. Multivariate analysis showed that participants in the 18–29 years age group, those with a secondary education level, the unemployed, and those who had been infected with HIV for 1–3 years were most likely to test positive for CMV infection. Joint and muscle pain were the most commonly reported symptoms among participants. Conclusions: The high seroprevalence of CMV IgM antibodies found in this study suggests that CMV infection is widespread in the study area. Therefore, it is essential to regularly screen HIV-positive individuals for CMV during routine antiretroviral therapy visits to enable early detection and improve treatment outcomes.